Tetra Bio-Pharma Inc - CEO & CRO, Dr. Guy Chamberland
Pharma Inc
Source: Tetra Bio Pharma Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Tetra Bio-Pharma Inc. (TBP), announced the positive results from an artificial intelligence study of Onternabez combined with Favipiravir
  • Onternabez helps mitigate the response in various targets of inflammatory conditions, and Favipiravir acts against different SARS-CoV-2 targets
  • These therapies against SARS-COV-2 created a new therapeutic that is expected to increase treatment efficacy and reduce the duration of the disease
  • The study also demonstrated that candidate ARDS-003, containing Onternabez, worked against various ARDS and Sepsis targets
  • Tetra Bio-Pharma Inc. (TBP) is up 40.00 per cent and is trading at $0.03 per share as of 1:14 p.m. EST

Cannabinoid drug developer, Tetra Bio-Pharma (TBP), announced positive results from an artificial intelligence study.

The company studied the efficacy of Onternabez combined with Favipiravir against acute respiratory distress syndrome (ARDS), Sepsis, and COVID-19.

Onternabez helps mitigate the response in various targets of inflammatory conditions, and Favipiravir acts against different SARS-CoV-2 targets. The interaction between Favipiravir and Onternabez against SARS-COV-2 created a new therapeutic that is expected to increase treatment efficacy and reduce the duration of the disease.

Tetra shared that the study demonstrated its candidate ARDS-003, which contained the pharmaceutical ingredient Onternabez, worked against various ARDS and Sepsis targets.

Tetra’s scientific approach has enabled them to develop a pipeline of other cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology.

The company has been working alongside Cellvera, a biopharmaceutical company that focuses on the commercial development of orally available nucleotide prodrugs.

Dr. Guy Chamberland, CEO and Chief Regulatory Officer at Tetra commented,

“This underscores our commitment with Cellvera to developing an innovative combination drug candidate to combat viral diseases… with Cellvera and the possibility of delivering the next scientific breakthroughs.”

Tetra Bio-Pharma Inc. (TBP) is up 40.00 per cent and is trading at $0.03 per share as of 1:14 p.m. EST.


More From The Market Herald

" One of the biggest players in B.C.’s Montney Fairway is ready to drill

For the past 80 years, the northeastern part of British Columbia has been home to a healthy petroleum exploration and development industry.

" @ the Bell: Growth-sensitive stocks fluctuate on mega jobs report

Canada’s main stock index ended on the higher side of flat on Friday trading as strength in the energy and technology sectors was weighed against

" Aimia (TSX:AIM) sells $7.36M in shares to Mithaq Capital

Aimia (AIM) has sold approximately $7.36 million of its common shares to investor company Mithaq Capital SPC.

" Terra Firma Capital (TSXV:TII) appoints new board member

Terra Firma Capital (TII) appoints Mike Kirchmair as a member of the corporation’s board of directors.